Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro

Citations Over TimeTop 17% of 2008 papers

Abstract

Activating mutations in the NRAS gene, which occur predominantly in codon 61 (Q61R, Q61K) are among the most common genetic events in malignant melanoma. NRAS protein with oncogenic codon 61 mutations may therefore be good therapeutic targets. In the present study, we used gene expression profiling as a method for global characterization of gene expression alterations that resulted from treatment of melanoma cells with siRNA specifically targeting NRAS(Q61R). Sixteen probe sets representing 15 unique genes were identified whose expression was significantly altered by siRNA against NRAS(Q61R) in 2 melanoma cell lines. The genes with altered expression are involved in several functions, including modulation of cell growth, invasion and migration. The results suggest that downregulation of cyclin E2 and cyclin D1 and also upregulation of the negative cell-cycle regulator HBP1 in NRAS(Q61R) knockdown cells contribute to the inhibition of cell proliferation. Furthermore, suppression of oncogenic NRAS results in reduced migration and invasion, which is accompanied by downregulation of EphA2 (a receptor tyrosine kinase), uPAR (urokinase receptor) and cytoskeleton proteins such as leupaxin, paxillin and vinculin. These studies support the concept that suppression of oncogenic NRAS by siRNA can induce growth arrest and inhibit invasion of human melanoma cells by modulating the levels of these gene products.

Related Papers

• → Fifteen-year quest for microphthalmia-associated transcription factor target genes(2009)350 cited
• → MITF in Normal Melanocytes, Cutaneous and Uveal Melanoma: A Delicate Balance(2022)83 cited
• → Microphthalmia‐Associated Transcription Factor (MITF) is Required but is Not Sufficient to Induce the Expression of Melanogenic Genes(2003)113 cited
• Microphthalmia-associated transcription factor (MITF) - from Waardenburg syndrome genetics to melanoma therapy(2010)
• → Investigation of the relationship between MITF and POU3F2 expression and the notion of a "genetic switch" underlying phenotype switching in melanoma.(2014)